# JUN 1 2 2013

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-nRNP/Sm autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay   
E. Applicant: EUROIMMUN US INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-nRNP/Sm ELISA (IgG)

G. Regulatory Information:

1. Requlation: 21 CFR 866.5110 - Antinuclear antibody immunological test system   
2. Classification: Class I   
3. Product code: LKO   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s): The EUROiMMUN Anti-nRNP/Sm ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against nRNP/Sm in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of mixed connective tissue diseases and systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

I. Device Description: The EUROIMMUN Anti-nRNP/Sm ELISA (IgG) consists of a microwell ELISA plate coated with nRNP/Sm antigen, calibrator, positive and negative control, peroxidase-labelled anti-human IgG conjugate, sample buffer, wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information: 1. Predicate device name (s): Inova Quanta Lite RNP ELISA 2. Predicate 510(k) number(s): K922833

# 3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to nRNP/Sm</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative evaluation</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Purified U1-nRNP complex; U1-nRNP contains RNP aswell as Sm reactive proteins</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrators and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate,followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>..Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcalculation of results), 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staf Recommendations for Anti-Nuclear Antibody (ANA) Test System Premarket (510(k)) Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample buffer, $1 0 0 ~ \mu \mu \up$ of each diluted patient sample and pre-diluted cnols a caliators added heantigen coaticotier well anincubatermintes  r temperatueAerincbatin themicotier wel srse washed with wash bufer  move antibodies and $1 0 0 ~ \mu \mu$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter well. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with EMPY $3 0 0 ~ \mu 1$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 ~ \mu \up$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu \up$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of 450 nm and a reference wavelength of between 620 nm and 650 nm within 30 minutes.

# M. Performance Characteristics (where applicable):

1 Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n =20</td><td rowspan=1 colspan=6>Anti-nRNP/Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.0-5.1</td><td rowspan=1 colspan=1>3.2-3.4</td><td rowspan=1 colspan=1>1.8-2.0</td><td rowspan=1 colspan=1>1.1 -1.2</td><td rowspan=1 colspan=1>0.7-0.9</td><td rowspan=1 colspan=1>0.3-0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 10 x 4</td><td rowspan=1 colspan=6>Anti-nRNP/Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.8-5.5</td><td rowspan=1 colspan=1>3.1-3.6</td><td rowspan=1 colspan=1>1.6-1.9</td><td rowspan=1 colspan=1>1.1-1.2</td><td rowspan=1 colspan=1>0.7-0.9</td><td rowspan=1 colspan=1>0.3-0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Tal al different lots with C samples distributed over the measurement range. The folowing results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-nRNP/Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*.</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>3.4 - 3.9</td><td rowspan=1 colspan=1>2.3-2.8</td><td rowspan=1 colspan=1>4.8- 5.7</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1>0.9-0.9</td><td rowspan=1 colspan=1>1.1 - 1.1</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=5>Anti-nRNP/Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>Sample 10</td><td rowspan=1 colspan=1>Sample 11</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>8.5</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.1- 0.3</td><td rowspan=1 colspan=1>3.1- 3.8</td><td rowspan=1 colspan=1>4.7-5.9</td><td rowspan=1 colspan=1>5.7-7.2</td><td rowspan=1 colspan=1>8.0-9.7</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.   
C. High dose Hook effect Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design of the Anti-nRNP/Sm ELISA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-nRNP/Sm ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection: Not applicable.

f. Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically.positive for antibodies against rib.P-P, SS-A, SS-B, Scl-70, Jo-1, centromeres, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-nRNP/Sm ELISA (IgG), so no cross reactivity is expected.

Inteerence: Toinvestigate thenluence from hemoglobin,riglycerides and bilibin, 5different at different anti-nRNP/Sm concentrations (ratio $0 . 9 \mathrm { ~ - ~ } 5 . 6 )$ were spiked with potential interfering substances and were incubated with the test system acording to the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $8 5 - 1 0 9 \%$ . No significant interference was observed for concentrations of up to EPY $1 0 0 0 \ m g / \mathsf { d } !$ for hemoglobin, $2 0 0 0 \ m g / \mathsf { d } !$ for triglyceride, $4 0 m g / d 1$ for bilirubin and 500 lU/ml for rheumatoid factor.

g. Assay cut-off: Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device.

A comparison study was performed using 287 clinically characterized samples (52 MCTD, 69 SLE, 51 Sjögren's syndrome, 15 systemic sclerosis, 15 fibromyalgia, 35 RA, 30 borreliosis and 20 healthy), obtained from different sources from Europe and North America. The panel consisted of 49 men and 238 women. Age ranged from 14 to 85 years with an average age of 46 years. AntinRNP/Sm antibodies are expected in either MCTD or SLE. The other disease groups serve as control cohorts. The samples were tested with the EUROIMMUN Anti-nRNP/Sm ELISA (gG) and with the Inova Quanta Lite RNP ELISA as the predicate device. Of the 8 discrepant samples, one was from a MCTD patient and the other 7 were from controls.

<table><tr><td colspan="4">All samples</td><td colspan="4">Predicate ELISA</td></tr><tr><td colspan="4">n = 287 EUROIMMUN</td><td colspan="2">positive</td><td colspan="2">negative</td></tr><tr><td>Anti-nRNP/Sm ELISA (IgG)</td><td colspan="4">positive</td><td>83</td><td colspan="2">0</td></tr><tr><td></td><td></td><td>negative</td><td></td><td></td><td>8</td><td></td><td>196</td></tr><tr><td>Negative agreement</td><td>196 1</td><td></td><td>196 . =</td><td>100.0%</td><td>95% C.I.:</td><td>98.1%</td><td>100.0%</td></tr><tr><td>Positive agreement</td><td>83 1</td><td>91</td><td>=</td><td>91.2%</td><td>95% C.I.:</td><td>83.4%</td><td>96.1%</td></tr><tr><td>Overall agreement</td><td>279 1</td><td>287</td><td>=</td><td>97.2%</td><td>95% C.I.:</td><td>94.6%</td><td>98.8%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept O; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. The comparison below satisfies this condition. Coefficients of determination were found to be above $0 . 9 9$ and $\%$ recovery compared toserum was in the range of 91 to $120 \%$ (serum = 100 %).

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>Citrate plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = plasma, x = serum)95% C.I. of intercept95% C.I. of slope</td><td rowspan=1 colspan=1>y = 0.46 + 0.98 x-0.56-2.410.95 - 1.01</td><td rowspan=1 colspan=1>y = -0.25 + 1.05 x-1.54 - 1.270.97 - 1.09</td><td rowspan=1 colspan=1>y = 0.37 + 1.04-1.72 - 1.82 .0.97 - 1.09</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination R²2</td><td rowspan=1 colspan=1>0.9988</td><td rowspan=1 colspan=1>0.9929</td><td rowspan=1 colspan=1>0.9915</td></tr><tr><td rowspan=1 colspan=1>Mean %recoveryRange of %recovery</td><td rowspan=1 colspan=1>101 %91 - 117 %</td><td rowspan=1 colspan=1>103 %92- 114 %</td><td rowspan=1 colspan=1>105 %93 - 120 %</td></tr></table>

# Clinical studies:

Clinical studies were performed in cooperation with diferent sites. In total 1046 clinically characterized samples (65 from MCTD patients, 404 from SLE patients, 151 from myositis patients and 426 from control groups) were investigated for anti-nRNP/Sm antibodies (lgG). With the EUROIMMUN Anti-nRNP/Sm ELISA (IgG) a prevalence of $100 . 0 \%$ $9 5 \%$ C.I.: $9 4 . 5 - 1 0 0 . 0 \% )$ was found in MCTD (clinical sensitivity) and a prevalence of $23 . 3 \%$ $9 5 \%$ C.I.: $1 9 . 2 - 2 7 . 7 \% )$ in SLE with a specificity of $9 9 . 3 \%$ $9 5 \%$ c.I.: $9 8 . 0 \mathrm { ~ - ~ } 9 9 . 9 \% )$ . The myositis panel was not considered for calculation of sensitivity and specificity, because anti-nRNP/Sm antibodies may occur in this disease [Tomer 1993]. The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

a. Clinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-nRNP/Sm ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.5-100.0%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>404</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>23.3%</td><td rowspan=1 colspan=1>19.2-27.7%</td></tr></table>

Clinical specificity.

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-nRNP/Sm ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>94.7%</td><td rowspan=1 colspan=1>* 89.8-97.7%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>97.8-100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.5- 100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Sjogren&#x27;s syndrome</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>92.0-99.7%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>98.4%</td><td rowspan=1 colspan=1>91.5-100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Borreliosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>577</td><td rowspan=1 colspan=1>566</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>96.6-99.9%</td></tr></table>

from the following groups:AlH $( n = 8 )$ , PBC $( n = 9 )$ , Grave's disease $( n = 1 2 )$ , Hashimoto $( \mathsf { n } = \mathsf { 1 1 } ) ,$ celiac disease $\tan = 1 1$ Diabetes Type I $( n = 1 2 )$

C. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off:

See Assay cut-ofi

5. Expected values/Reference range:

The levels of anti-nRNP/Sm antibodies (IgG) were analyzed in a panel of 200 samples from apparently healthy blood donors (120 men and 80 women with an average age of 40 y; age range: 19 - 68 y). The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>199</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.09</td></tr></table>

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in his premarket notification s complete and supports a substantial equivalence decision.

ATTACHMENT 1

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-Sm autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay   
E. Applicant: EUROIMMUN US INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-Sm ELISA (IgG)

G. Regulatory Information:

1. Regulation: 21 CFR 866.5110 - Antinuclear antibody immunological test system   
2. Classification: Class II   
3. Product code: LKP   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s): The EUROiMMUN Anti-Sm ELISA (IgG) test kit is intended for the qualitative of IgG class autoantibodies aainst Sm inhuman serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

I. Device Description: The EUROIMMUN Anti-Sm ELISA (IgG) consists of a microwell ELISA plate coated with Sm antigen calirator positivnd negative control peroidase-abelle antihuman IgG conjugatesample bufer wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information:

1. Predicate device name (s): Inova Quanta Lite Sm ELISA   
2. Predicate 510(k) number(s): K922831

# 3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to Sm</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative units</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Purified Sm antigen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-welil antigen coated plate,followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>&quot;Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcalculation of results), 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance orIndustry nd FA StRecomendationsorntiNuclear Antibody ANA)Tes System Premarket (510(k)) Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample buffer, $1 0 0 ~ \mu \mu$ of each diluted patient sample and pre-diluted controls an calrators ade  heantigen coatmicotier wel andincubated or 0mues temperature. Afer incubation the micotiter well strips are washed with wash buffer to emove unbound anodies an0  eanti-human Genzyme conjugate reagent  ded toeachmirotiter welAe an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with EY $3 0 0 ~ \mu \up$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 \ \mu \up$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 \ \mu 1$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of 450 nm and a reference wavelength of between 620 nm and $6 5 0 \mathsf { n m }$ within 30 minutes.

# M. Performance Characteristics (where applicable):

1Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.4-5.8</td><td rowspan=1 colspan=1>3.5 - 3.9</td><td rowspan=1 colspan=1>1.9- 2.0</td><td rowspan=1 colspan=1>1.2-1.3</td><td rowspan=1 colspan=1>0.7-0.9</td><td rowspan=1 colspan=1>0.4 - 0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 10 x 4</td><td rowspan=1 colspan=6>Anti-Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.3- 7.4</td><td rowspan=1 colspan=1>3.5-4.6</td><td rowspan=1 colspan=1>1.5-2.2</td><td rowspan=1 colspan=1>1.0- 1.2</td><td rowspan=1 colspan=1>0.6- 1.0</td><td rowspan=1 colspan=1>0.3-0.5</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>100%</td></tr></table>

The lot to lot reproducibility was investigated during thevalidaton and qualitycontrol of the it using different lots with QC samples distributed over the measurement range. The following results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>· 0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>3.3-3.9</td><td rowspan=1 colspan=1>3.2-3.9</td><td rowspan=1 colspan=1>2.9-3.4</td><td rowspan=1 colspan=1>0.3-0.3</td><td rowspan=1 colspan=1>0.8-0.9</td><td rowspan=1 colspan=1>1.1 - 1.3</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=5>Anti-Sm ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>Sample 10</td><td rowspan=1 colspan=1>Sample 11</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>9*</td><td rowspan=1 colspan=1>10**</td><td rowspan=1 colspan=1>10^</td><td rowspan=1 colspan=1>9**</td><td rowspan=1 colspan=1>10**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.0 - 0.2</td><td rowspan=1 colspan=1>1.5- 2.2</td><td rowspan=1 colspan=1>2.6-3.8</td><td rowspan=1 colspan=1>4.9-6.7</td><td rowspan=1 colspan=1>7.5-9.6</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs

b. Linearity/assay reportable range: Not applicable.

C. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites $\because$ EMPY saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design of the Anti-Sm ELISA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-Sm ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection: Not applicable

Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically positive for antibodies against rib.P-P, nRNP/Sm, SS-A, SS-B, Scl-70, Jo-1, centromeres, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-Sm ELISA (IgG), so no cross reactivity is expected.

Intererence: To investigate thenflence from hemoglobin,triglycerides and biliubin 5different s at different anti-Sm concentrations (ratio $0 . 7 - 3 . 9 )$ were spiked with potential interfering substances and were incubated with the test system according to .the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $9 0 - 1 1 1 \%$ . No significant interference was observed for conicentrations of up to EMPY $1 0 0 0 \ m g / { \mathsf { d } } |$ for hemoglobin, $2 0 0 0 \ m g / \mathsf { d } |$ for triglyceride, $4 0 \ m { \tt g } / { \tt d } { \tt l }$ for bilirubin and $5 0 0 ~ ! \cup / m !$ for rheumatoid factor.

g. Assay cut-off: Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device:

A comparison study was performed using 294 clinically characterized samples (128 SLE, 51 Sjögren's syndrome, 15 systemic sclerosis, 15 fibromyalgia, 35 RA, 30 borreliosis and 20 healthy). obtained from different sources from Europe and North America. The panel consisted of 60 men and 234 women. Age ranged from 14 to 85 years with an average age of 45 years. Anti-Sm antibodies are expected in SLE. The other disease groups serve as control cohorts. The samples were tested with the EUROIMMUN Anti-Sm ELISA (IgG) and with the Inova Quanta Lite Sm ELISA as the predicate device. The results are shown in the table below. All of the 7 discrepant samples negative in the EUROIMMUN test were from controls. The 5 discrepant samples positive in the EUROiMMUN test were from SLE patients.

<table><tr><td rowspan="2" colspan="4">All samples n = 294</td><td rowspan="2">Predicate ELISA</td><td colspan="3"></td></tr><tr><td></td><td>positive</td><td>negative</td></tr><tr><td rowspan="2">EUROIMMUN Anti-Sm ELISA (IgG)</td><td colspan="4">positive</td><td>37</td><td colspan="2">5</td></tr><tr><td></td><td>negative</td><td></td><td></td><td>7</td><td></td><td>. 245</td></tr><tr><td>Negative agreement</td><td>245 /</td><td>250</td><td></td><td></td><td>98.0%</td><td>95% C.I.: 95.4%</td><td>99.3%</td></tr><tr><td>Positive agreement</td><td>37 1</td><td></td><td>44</td><td>=</td><td>84.1%</td><td>95% C.I.: 69.9%</td><td>93.4%</td></tr><tr><td>Overall agreement</td><td>282</td><td>1 294</td><td></td><td>=</td><td>95.9%</td><td>95% C.I.: 93.0%</td><td>97.9%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept O; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.99 and %recovery compared to serum was in the range of 89 to $118 \%$ $( \mathsf { s e r u m } = 1 0 0 \% )$

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>Citrate plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = plasma, x = serum)95% C.I. of intercept95% C.I. of slope</td><td rowspan=1 colspan=1>y = 0.33 + 1.00.x-0.32 - 1.240.96 - 1.03</td><td rowspan=1 colspan=1>y = 0.19 + 0.97 x-0.92 - 1.950.94 - 1.01</td><td rowspan=1 colspan=1>y = 0.05 + 1.02-0.69 - 3.270.99 - 1.05</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination R²</td><td rowspan=1 colspan=1>0.9953</td><td rowspan=1 colspan=1>0.9948</td><td rowspan=1 colspan=1>0.9931</td></tr><tr><td rowspan=1 colspan=1>Mean %recoveryRange of %recovery</td><td rowspan=1 colspan=1>102 %94 - 115 %</td><td rowspan=1 colspan=1>99 %90- 111 %</td><td rowspan=1 colspan=1>103 %89 - 118 %</td></tr></table>

Clinical studies:

Clinical studies were performed in cooperation with different sites. In total 1036 clinically characterized samples (414 from SLE patients and 622 from control groups) were investigated for anti-Sm antibodies $( 1 9 6 )$ . With the EUROIMMUN Anti-Sm ELISA $( \beta \ g G )$ a prevalence of $1 1 . 4 \%$ $9 5 \%$ C.I.: $8 . 5 - 1 4 . 8 \% )$ was found in SLE with a specificity of $9 9 . 0 \%$ $9 5 \%$ C.I.: $9 7 . 9 - 9 9 . 6 \%$ . The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

aClinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-Sm ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>414</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>11.4%</td><td rowspan=1 colspan=1>8.5-14.8%</td></tr></table>

Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-Sm ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>. %</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>97.8- 100.0%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.5 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Sjögren&#x27;s syndrome</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.9- 100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>97.6- 100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>86.7%</td><td rowspan=1 colspan=1>73.2-94.9%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Borreliosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>622</td><td rowspan=1 colspan=1>616</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>97.9-99.6%</td></tr></table>

\*from the following groups: AlH $( n = 8 )$ , PBC $( n = 9 )$ , Grave's disease $( n = 1 2 )$ , Hashimoto $( n = 1 1 )$ , celiac disease $( \mathsf { n } = \mathsf { 1 1 } )$ Diabetes Type I $( n = 1 2 )$

Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-Sm antibodies (lgG) were analyzed in a panel of 200 samples from apparently healthy blood donors (120 men and 80 women with an average age of 40 y; age range: 19 - 68 y). The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>cYanmaGYelowb</td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.02</td></tr></table>

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence.   
decision.

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-SS-A autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay   
E. Applicant: EUROIMMUN US INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-SS-A ELISA (IgG)

G. Regulatory Information: 1. Regulation: 21 CFR 866.5100 - Antinuclear antibody immunological test system 2. Classification: Class II 3. Product code: LLL 4. Panel: Immunology

H. Intended Use:

1. Intended use(s):: The EUROlMMUN Anti-SS-A ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against SS-A in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of Sjögren's syndrome and systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

I: Device Description:

The EUROIMMUN Anti-SS-A ELISA (IgG) consists of a microwell ELISA plate coated with SS-A antigen, clibrator positive and negative control peroxidase-abelled antihuman gGconjugate, sample buf wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information:

1. Predicate device name (s): Inova Quanta Lite SS-A ELISA   
2. Predicate 510(k) number(s): K922830

# 3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to SS-A</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative units</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Purified SS-A antigen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate,followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>.,Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcatculation of results). 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staff Recommendations for Anti-Nuclear Antibody (ANA) Test System Premarket (510(k)) Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample buffer, $1 0 0 ~ \mu \vert$ of each diluted patient sample and pre-diluted conols and alirators aeaded t theantigen coatemicrotier wel and incubatedor 30minutes at ro temperature. After incubation the microtiter well strips are washed with wash buffer to remove unbound antibodies and $1 0 0 \ \mu 1$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter wel. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with ${ 3 0 0 } ~ \mu !$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 \ \mu \up$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu \mu \up$ stop solution is added. The microtiter plates are placed in an ELlSA reader and read at a wavelength of $4 5 0 \mathsf { \Omega } \mathsf { n m }$ and a reference wavelength of between 620 nm and $6 5 0 \mathsf { n m }$ within 30 minutes.

# M. Performance Characteristics (where applicable):

# 1. Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day, each run performed according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-SS-A ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.9-6.4</td><td rowspan=1 colspan=1>4.0 - 4.5</td><td rowspan=1 colspan=1>1.9-2.1</td><td rowspan=1 colspan=1>1.2-1.4</td><td rowspan=1 colspan=1>0.7-0.8</td><td rowspan=1 colspan=1>0.3-0.3</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 10 x 4</td><td rowspan=1 colspan=6>Anti-SS-A ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>· 1.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.0-6.4</td><td rowspan=1 colspan=1>3.7-4.5</td><td rowspan=1 colspan=1>1.6-1.9</td><td rowspan=1 colspan=1>1.0-1.4</td><td rowspan=1 colspan=1>0.7-0.9</td><td rowspan=1 colspan=1>0.3- 0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

The lot to lot reproducibility was investigated during the validaton and qualy control of the kit sing different lots with QC samples distributed over the measurement range. The following results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-SS-A ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.4-4.8</td><td rowspan=1 colspan=1>5.1-6.2</td><td rowspan=1 colspan=1>5.1-6.0</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1>0.9-0.9</td><td rowspan=1 colspan=1>1.1- 1.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=5>Anti-SS-A ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>Sample 10</td><td rowspan=1 colspan=1>Sample 11</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>10**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>10**</td><td rowspan=1 colspan=1>9**</td><td rowspan=1 colspan=1>11**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.1- 0.2</td><td rowspan=1 colspan=1>1.3-1.8</td><td rowspan=1 colspan=1>2.3-3.1</td><td rowspan=1 colspan=1>4.3 - 5.2</td><td rowspan=1 colspan=1>7.4-8.3</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.

c. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design of the Anti-SS-A ELISA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-SS-A ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection: Not applicable.

f. Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically positive for antibodies against rib.P-P, nRNP/Sm, Sm, Scl-70, Jo-1, centromeres, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-SS-A ELISA (IgG), so no cross reactivity is expected.

Intrerence: Toinvestigate theinflence from hemoglobin, triglycerides and biliubin, 5 different s at different anti-SS-A concentrations (15 - 124 RU/ml) were spiked with potential interfering substances and were incubated with the test system according to the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $9 3 - 1 0 7 \%$ . No significant interference was observed for concentrations of up to $1 0 0 0 \ m g / \mathsf { d } |$ for hemoglobin, 2000 mg/dl for triglyceride, 40 mg/dl for bilirubin and 500 lU/ml for rheumatoid factor.

g. Assay cut-off: Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device

A comparison study was performed using 305 clinically characterized samples (63 SLE, 77 Sjögren's syndrome, 23 systemic sclerosis, 1 SSc/SS, 15 fibromyalgia, 26 myositis, 35 RA, 30 borreliosis, 20 healthy), obtained from different sources from Europe and North America. The panel consisted of 54 men and 251 women. Age ranged from 14 to 85 years with an average age of 48 years. Anti-SS-A antibodies are expected in either Sjögren's syndrome or SLE. The other disease groups serve as control cohorts. The samples were tested with the EUROIMMUN Anti-SS-A ELISA (IgG) and with the Inova Quanta Lite SS-A ELISA as the predicate device. Of the 9 discrepant samples negative in the EUROlMMUN test, 2 were from patients with Sjögren's syndrome and one from a SLE patient, the other 6 were from controls. All 3 discrepant samples positive in the EUROlMMUN test were from SLE patients.

<table><tr><td colspan="4">All samples</td><td colspan="4">Predicate ELISA</td></tr><tr><td colspan="4" rowspan="2">n = 305 EUROIMMUN positive</td><td colspan="3">positive</td></tr><tr><td></td><td>116</td><td>negative 3</td></tr><tr><td rowspan="2">Anti-SS-A ELISA (IgG)</td><td colspan="3">negative</td><td colspan="2">9</td><td colspan="2">177</td></tr><tr><td>177 /</td><td>180</td><td>=</td><td>98.3%</td><td>95% C.I.:</td><td>95.2%</td><td>99.7%</td></tr><tr><td>Negative agreement Positive agreement</td><td>116 1</td><td>125</td><td>=</td><td>92.8%</td><td></td><td>86.8% -</td><td>96.7%</td></tr><tr><td>Overall agreement</td><td>293 1</td><td>·305</td><td>=</td><td>96.1%</td><td></td><td>95% C.1.: 95% C.I.: 93.2%</td><td>98.0% -</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept 0; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.99 and %recovery compared to serum was in the range of 85 to $104 \%$ $( \mathsf { s e r u m } = 1 0 0 \% )$ .

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>Citrate plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = plasma, x = serum)95% C.I. of intercept95% C.1. of slope</td><td rowspan=1 colspan=1>y = -1.59 + 0.99 x-4.49 - 3.010.95 - 1.02</td><td rowspan=1 colspan=1>y = -1.47 + 0.99 x-4.62 - 1.360.95 - 1.02</td><td rowspan=1 colspan=1>y = -0.54 + 0.98-4.65 - 3.320.94 - 1.04</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination </td><td rowspan=1 colspan=1>0.9972</td><td rowspan=1 colspan=1>0.9929</td><td rowspan=1 colspan=1>0.9956</td></tr><tr><td rowspan=1 colspan=1>Mean %recoveryRange of %recovery</td><td rowspan=1 colspan=1>97 %90 - 102 %</td><td rowspan=1 colspan=1>95 %85- 102 %</td><td rowspan=1 colspan=1>98 %93- 104 %</td></tr></table>

# Clinical studies:

Clinical studies were performed in cooperation with different sites. In total 1026 clinically characterized samples (88 from SS patients, 404 from SLE patients and 534 from control groups) were investigated for anti-SS-A antibodies $( \log G )$ . With the EUROIMMUN Anti-SS-A ELISA (IgG) a prevalence of $73 . 9 \%$ $( 9 5 \%$ EPY C.I.: $6 3 . 4 - 8 2 . 7 \% )$ was found in Sjögren's syndrome (clinical sensitivity) and a prevalence of $40 . 6 \%$ $( 9 5 \%$ C.I.: $3 5 . 8 - 4 5 . 6 \% )$ was found in SLE with a specificity of $9 4 . 8 \%$ $9 5 \%$ C.I.: $9 2 . 5 - 9 6 . 5 \%$ Systemic sclerosis and myositis panels were considered for calculation  specificity, however, it has been reorted that anti-SS-A antibodies may occur in these diseases [Antonioli 2002, Ghirardello 2005]. The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

a. Clinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>nti-SS-A EL</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Sjögren&#x27;s syndrome</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>73.9%</td><td rowspan=1 colspan=1>63.4- 82.7%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>404</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>40.6%</td><td rowspan=1 colspan=1>35.8-45.6%</td></tr></table>

Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Anti-SS-A ELISA (IgG)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>92.6%</td><td rowspan=1 colspan=1>84.6-97.2%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>91.4%</td><td rowspan=1 colspan=1>85.7-95.3%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>93.0-99.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>91.1%</td><td rowspan=1 colspan=1>78.8 -97.5%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Borreliosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>534</td><td rowspan=1 colspan=1>506</td><td rowspan=1 colspan=1>94.8%</td><td rowspan=1 colspan=1>92.5-96.5%</td></tr></table>

\*from the following groups: AlH $( n = 8 )$ , PBC $( n = 9 )$ ,Grave's disease $( n = 1 2 )$ , Hashimoto $( \mathsf { n } = \mathsf { 1 } 1 )$ , celiac disease $( n = 1 1 )$ + Diabetes Type I $( n = 1 2 )$

C. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-SS-A antibodies (IgG) were analyzed in a panel of 200 samples from apparently healthy blood donors (120 men and 80 women with an average age of $4 0 y ;$ age range: $1 9 - 6 8 y )$ . The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>198</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.33</td></tr></table>

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-SS-B autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay

E. Applicant: EUROIMMUN US INC.

F. Proprietary and Established Names: EUROIMMUN Anti-SS-B ELISA (IgG)

G. Regulatory Information:

1. Regulation: 21 CFR 866.5110 - Antinuclear antibody immunological test system   
2. Classification: Class II   
3. Product code: LLL   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s): The EUROlMMUN Anti-SS-B ELISA (lIgG) test kit is intended for the qualitative determination of IgG class autontibodies against SS-B in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an id in the diagnosis of Sjögren's syndrome and systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.   
2. Indication(s) for use Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

I. Device Description:

Te EUROMMU Anti-S- ELISA (IgGconsists a microwel ELISA plate coated with SS- nigen calirator, positive nd negative contro, peroxidase-abelled antihuman gGconjugate, ample bur wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information:

1. Predicate device name (s): Inova Quanta Lite SS-B ELISA   
2. Predicate 510(k) number(s): K922832

# 3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to SS-B</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative units</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Purified SS-B antigen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate,followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>.,Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive. 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcalculation of results). 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staf: Recommendations for Anti-Nuclear Antibody (ANA) Test System Premarket (510(k)) Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample. buffer, $1 0 0 \ \mu \up$ of each diluted patient sample and pre-diluted conols nd calibrators eaed t heantigen coatemicrotier wel anncubatedor 30minutes  r temperature. After incubation the microtiter well strips are washed with wash buffer to remove unbound antibodies and $1 0 0 \mu$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter wel. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with $3 0 0 ~ \mu \mu$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 ~ \mu \nu$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu \up$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of $4 5 0 n m$ and a reference wavelength of between 620 nm and 650 nm within 30 minutes.

# M. Performance Characteristics (where applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day, each run performed according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-SS-B ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.0-4.3</td><td rowspan=1 colspan=1>2.8-3.1</td><td rowspan=1 colspan=1>1.1-1.4</td><td rowspan=1 colspan=1>0.7-0.9</td><td rowspan=1 colspan=1>0.5-0.7</td><td rowspan=1 colspan=1>0.4-0.5</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 10 x 4</td><td rowspan=1 colspan=6>Anti-SS-B ELISA (IgG)Ratio                                        .</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.2-5.3</td><td rowspan=1 colspan=1>3.0-3.7</td><td rowspan=1 colspan=1>1.3-1.7</td><td rowspan=1 colspan=1>1.0-1.1</td><td rowspan=1 colspan=1>0 5.-.0.7</td><td rowspan=1 colspan=1>0.4-0.5</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

The lot to lot eproduciblity wasinvestigated durig the validaton and qualiy control f the  usin different lots with QC samples distributed over the measurement range. The following results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-SS-B ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>3.6- 4.2</td><td rowspan=1 colspan=1>3.4 - 4.4</td><td rowspan=1 colspan=1>3.3- 4.1</td><td rowspan=1 colspan=1>0.3-0.3</td><td rowspan=1 colspan=1>0.9-0.9</td><td rowspan=1 colspan=1>1.1-1.3</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Anti-SS-B ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>7.7</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>2.3- 3.1</td><td rowspan=1 colspan=1>3.2-4.8</td><td rowspan=1 colspan=1>7.0-8.8</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.

c. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design o the Anti-SS-B ELISA (igG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-SS-B ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection:

Not applicable.

Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically positive for antibodies against rib.P-P, nRNP/Sm, Sm, SS-A, Scl-70, Jo-1, centromeres, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-SS-8 ELISA (IgG), so no cross reactivity is expected.

Interference: Toinvestigate the influence from hemoglobin, triglycerides and bilirubin 5 different s at different anti-SS-B concentrations (18 - 123 RU/ml) were spiked with potential interfering substances and were incubated with the test system according to the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $9 2 - 1 1 6 \%$ . No significant interference was observed for concentrations of up to EMPY $1 0 0 0 \ m g / \mathsf { d } \mathsf { i }$ for hemoglobin, 2000 mg/dl for triglyceride, 40 mg/dl for bilirubin and 500 lU/ml for rheumatoid factor.

g. Assay cut-off: Ratio 1.0

2 Comparison studies:

a. Method comparison with predicate device.

A comparison study was performed using 275 clinically characterized samples (57 SLE, 64 Sjögren's syndrome, 23 systemic sclerosis, 1 SSc/SS, 4 SLE/SS, 15 fibromyalgia, 26 myositis, 35 RA, 30 borreliosis and 20 healthy), obtained from different sources from Europe and North America. The panel consisted of 55 men and 220 women. Age ranged from 12 to 83 years with an average age of 48 years. Anti-SS-B antibodies are expected in either Sjögren's syndrome or SLE. The other disease groups serve as control cohorts. The samples were tested with the EUROlMMUN Anti-SS-B ELISA (IgG) and with the Inova Quanta Lite SS-B ELISA as the predicate device. Of the 3 discrepant samples negative in the EUROlMMUN test, one was from a Sjögren's syndrome patient and the other 2 were from controls. The discrepant sample positive in the EUROiMMUN test was from a Sjögren's syndrome patient.

<table><tr><td colspan="5">All samples</td><td colspan="3">Predicate ELISA negative</td></tr><tr><td colspan="5">n = 275</td><td colspan="2">positive</td></tr><tr><td>EUROIMMUN Anti-SS-B ELISA (IgG)</td><td></td><td>positive</td><td></td><td></td><td>82</td><td>1 189</td></tr><tr><td></td><td colspan="3">negative</td><td colspan="2">3</td></tr><tr><td>Negative agreement</td><td>189 /</td><td>190</td><td>=</td><td>99.5%</td><td>95% C.I.: 97.1%</td><td>100.0%</td></tr><tr><td>Positive agreement</td><td>82 1</td><td>85</td><td>=</td><td>96.5%</td><td>95% C.I.: 90.0%</td><td>99.3%</td></tr><tr><td>Overall agreement</td><td>271 ,</td><td>275</td><td>=</td><td>98.5%</td><td>95% C.I.: 96.3%</td><td>99.6%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept 0; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.99 and %recovery compared toserum was in the range of 78 to $116 \%$ $( \mathsf { s e r u m } = 1 0 0 \% )$ .

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>Citrate plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = plasma, x = serum)95% C.I. of intercept95% C.I. of slope</td><td rowspan=1 colspan=1>y = -1.56 + 1.05 x-5.46 - 0.191,04-1.09</td><td rowspan=1 colspan=1>y = -0.22 + 1.06 x-3.29- 2.281.01 - 1.09</td><td rowspan=1 colspan=1>y = 0.55 + 1.01-1.56 - 5.620.97 - 1.05</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination R</td><td rowspan=1 colspan=1>0.9972</td><td rowspan=1 colspan=1>0.9968</td><td rowspan=1 colspan=1>0.9951</td></tr><tr><td rowspan=1 colspan=1>Mean %recoveryRange of %recovery</td><td rowspan=1 colspan=1>100 %78-116 %</td><td rowspan=1 colspan=1>105 %98 - 116 %</td><td rowspan=1 colspan=1>101 %81 - 110 %</td></tr></table>

3Clinical studies:

Clinical studies were performed in cooperation with different sites. In total 1026 clinically characterized samples (88 from SS patients, 404 from SLE patients and 534 from control groups) were investigated for anti-SS-B antibodies (IgG). With the EUROIMMUN Anti-SS-B ELISA (IgG) a prevalence of $3 9 . 8 \%$ $( 9 5 \%$ C.I.: $2 9 . 5 - 5 0 . 8 \% )$ was found in Sjögren's syndrome and a prevalence of $1 3 . 9 \%$ $9 5 \%$ C.I.: $1 0 . 6 - 1 7 . 6 \% )$ was found in SLE with a specificity of $9 8 . 1 \%$ $9 5 \%$ C.I.: $9 6 . 6 - 9 9 . 1 \% )$ . The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

a. Clinical sensitivity.

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Sjogren&#x27;s syndrome</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>39.8%</td><td rowspan=1 colspan=1>29.5 -50.8%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>404</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>13.9%</td><td rowspan=1 colspan=1>10.6-17.6%</td></tr></table>

Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-SS-B ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>96.6-100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>95.1%</td><td rowspan=1 colspan=1>87.8 - 98.6%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>95.3-99.8%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>81.7-98.6%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Borreliosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>534</td><td rowspan=1 colspan=1>524</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>96.6 -99.1%</td></tr></table>

'from the following groups: AIH $\{ \boldsymbol { \mathsf { n } } = \boldsymbol { \mathsf { 8 } } \}$ , PBC $( n = 9 )$ , Grave's disease $( n = 1 2$ Hashimoto ${ \mathrm { ( n } } = 1 1 { \mathrm { ) } }$ , celiac disease $( \mathsf { n } = \mathsf { 1 1 } )$ . Diabetes Type I $( n = 1 2 )$

c. Other clinical supportive data (when a. and b. are not applicable):

4Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-SS-B antibodies (IgG) were analyzed in a panel of 200 samples from apparently healthy blood donors (120 men and 80 women with an average age of 40 y; age range: $1 9 - 6 8 \ y ,$ The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0:02</td></tr></table>

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted inormation in this premarket notification is compleeand supports a substantial equivalence decision.

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-Scl-70 autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay   
E. Applicant: EUROIMMUN US INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-Scl-70 ELISA (IgG)

G.Regulatory Information:

1. Regulation: 21 CFR 866.5110 - Antinuclear antibody immunological test system   
2. Classification: Class II   
3. Product code: LLL   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s): The EUROiMMUN Anti-Scl-70 ELISA (IgG) test kit is intended for the qualitative determination of IgG clas autoantibodies against Scl-70 in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosisof progressive systemic sclerosis, in conjuncion withother aboratory an cal findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

# I. Device Description:

Th EUROIMMUN AntiScl-70 ELISA gG consists  a microwell ELISA plate coated with Scl-70antigen, caliator, positiveand negative control peroxidase-abelle anti-human IgGconjugate, sample buf wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information: 1. Predicate device name (s): Inova Quanta Lite Scl-70 ELISA 2. Predicate 510(k) number(s): K924898

# 3.Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to Scl-70</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative units</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Purified Scl-70 antigen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate.followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>&quot;.Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcalculation of results). 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Sta Recommendations orAnti-Nuclear Antibody (ANA) Test System Premarket $( 5 1 0 ( k ) )$ Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample buffer, $1 0 0 \ \mu \up$ of each diluted patient sample and pre-diluted controls and calrators edded  theantigen coatd micotiter wel and incubated or 3minutes t r temperature. After incubation the microtiter well strips are washed with wash buffer toremove unbound antibodies and $1 0 0 \mu |$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter well. After an additional 30-minutes incubation at room temperature, the microtiter well are again washed 3 times with $3 0 0 ~ \mu \nu$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 \mu !$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu \up$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of 450 nm and a reference wavelength of between 620 nm and 650 nm within 30 minutes.

# M.Performance Characteristics (where applicable):

# 1 Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day, each run performed according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-Scl-70 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.8-6.7</td><td rowspan=1 colspan=1>3.8-4.5</td><td rowspan=1 colspan=1>2.0-2.3</td><td rowspan=1 colspan=1>1.3-1.5</td><td rowspan=1 colspan=1>0.7-0.9</td><td rowspan=1 colspan=1>0.3-0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>·100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 10 x 4</td><td rowspan=1 colspan=6>Anti-Scl-70 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.7-7.0</td><td rowspan=1 colspan=1>3.7-4.7</td><td rowspan=1 colspan=1>1.7 - 2.2</td><td rowspan=1 colspan=1>1.1 - 1.4</td><td rowspan=1 colspan=1>0.7- 0.9</td><td rowspan=1 colspan=1>0.2- 0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

different lots with C samples distributed over the measurement range. The following results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-Scl-70 ELISA (IgG)Ratio                               ·.</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.0-5.0</td><td rowspan=1 colspan=1>4.1-5.4</td><td rowspan=1 colspan=1>3.3- 3.8</td><td rowspan=1 colspan=1>0.3-0.3</td><td rowspan=1 colspan=1>0.8-0.9</td><td rowspan=1 colspan=1>1.0 - 1.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Anti-Scl-70 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>10**</td><td rowspan=1 colspan=1>11**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>6.2</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>2.5-3.7</td><td rowspan=1 colspan=1>4.3-5.7</td><td rowspan=1 colspan=1>5.3-6.8</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.

C. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design of the Anti-Scl-70 ELiSA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

dTraceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-Scl-70 ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection: Not applicable.

f. Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically positive for antibodies against rib.P-P, nRNP/Sm, Sm, SS-A, SS-B, Jo-1, centromeres, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-Scl-70 ELISA (IgG), so no cross reactivity is expected.

Intrerence: Toinvestigate thenflence from hemoglobin, triglycrides and biliubin, 5different at different anti-Scl-70 concentrations $( 1 7 - 1 0 0 ) \textcircled { \times } ( 1 / m ! )$ were spiked with potential interfering substances and were incubated with the test system according to the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $8 6 - 1 0 9 \%$ . No significant interference was observed for concentrations of up to EMPY $1 0 0 0 ~ \mathsf { m g / d l }$ for hemoglobin, $2 0 0 0 \ m g / \mathsf { d } \mathsf { I }$ for triglyceride, 40 mg/dl for bilirubin and 500 lU/ml for rheumatoid factor.

g. Assay cut-off: Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device.

A comparison study was performed using 309 clinically characterized samples (158 systemic sclerosis, 51 Sjögren's syndrome, 15 fibromyalgia, 35 RA, 30 borreliosis and 20 healthy), obtained from different sources from Europe and North America. The panel consisted of 62 men and 247 women. Age ranged from 14 to 88 years with an average age of 53 years. Anti-Scl-70 antibodies are expected in systemic sclerosis. The other disease groups serve as control cohorts. The samples were tested with the EUROIMMUN Anti-Scl-70 ELISA (IgG) and with the Inova Quanta Lite Scl-70 ELISA as the predicate device.

<table><tr><td colspan="4">All samples</td><td colspan="4">Predicate ELISA</td></tr><tr><td colspan="4">n = 309 EUROIMMUN</td><td colspan="2">positive</td><td colspan="2">negative</td></tr><tr><td rowspan="2">Anti-Scl-70 ELISA (IgG)</td><td colspan="3">positive</td><td colspan="2">125</td><td colspan="2">0</td></tr><tr><td>negative</td><td></td><td></td><td></td><td>0</td><td></td><td>184</td></tr><tr><td>Negative agreement</td><td>184 1</td><td>184</td><td>. =</td><td>100.0%</td><td>95% C.I.:</td><td>98.0%</td><td>100.0%</td></tr><tr><td>Positive agreement</td><td>125 1</td><td>125</td><td>=</td><td>100.0%</td><td>95% C.1.:</td><td>97.1%</td><td>100.0%</td></tr><tr><td>Overall agreement</td><td>309 1</td><td>309</td><td>=</td><td>100.0%</td><td>95% C.I.:</td><td>98.8%</td><td>100.0%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept O; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.98 and %recovery compared toserum was in the range of 86 to $113 \%$ EMPY $( s e r u m = 1 0 0 \% )$ .

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>Citrate plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>.16</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = plasma, x = serum)95% C.I. of intercept95% C.I. of slope</td><td rowspan=1 colspan=1>y = -0.58 + 1.00 x-3.25-2.240.94 - 1.06</td><td rowspan=1 colspan=1>y = 0.17 + 1.02x-1.99 - 1.640.98 - 1.06</td><td rowspan=1 colspan=1>y = - 0.87 + 0.97-2.02 - 1.350.94-1.03</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination R</td><td rowspan=1 colspan=1>0.9895</td><td rowspan=1 colspan=1>0.9930</td><td rowspan=1 colspan=1>0.9953</td></tr><tr><td rowspan=1 colspan=1>Mean %recoveryRange of %recovery</td><td rowspan=1 colspan=1>98 %86 - 107 %</td><td rowspan=1 colspan=1>101 %92-113 %</td><td rowspan=1 colspan=1>96 %87 - 103 %</td></tr></table>

3Clinical studies:

Clinical studies were performed in cooperation with different sites. In total 909 clinically characterized samples (280 from systemic sclerosis patients and 629 from control groups) were investigated for antiScl-70 antibodies (IgG). With the EUROlMMUN Anti-Scl-70 ELISA (IgG) a prevalence of $23 . 2 \%$ $( 9 5 \%$ EMPY C.I.: $1 8 . 4 - 2 8 . 6 \%$ )was found in systemic sclerosis, a prevalence of $5 9 . 4 \%$ $9 5 \%$ C.I.: $4 8 . 9 - 6 9 . 3 \% )$ was found in diffuse systemic sclerosis and a prevalence of $5 . 3 \%$ $( 9 5 \%$ C.I.: $2 . 0 - 1 1 . 2 \% )$ was found in limited systemic sclerosis with a specificity of $9 9 . 8 \%$ $9 5 \%$ C.I.: $9 9 . 1 \mathrm { ~ - ~ } 1 0 0 . 0 \%$ .The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

aClinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-Scl-70 ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>23.2%</td><td rowspan=1 colspan=1>18.4 - 28.6%</td></tr><tr><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>Diffuse systemic sclerosis (from panel 1)</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>59.4%</td><td rowspan=1 colspan=1>48.9-69.3%</td></tr><tr><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>Limited systemic sclerosis (from panel 1)</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>2.0-11.2%</td></tr></table>

b Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-Scl-70 ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>98.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>86.8- 100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>96.6- 100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Sjogren&#x27;s syndrome</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.9 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>92.1 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Borreliosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4- 100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>629</td><td rowspan=1 colspan=1>628</td><td rowspan=1 colspan=1>99.8%</td><td rowspan=1 colspan=1>99.1 - 100.0%</td></tr></table>

\*from the following groups: AlH $( n = 8 )$ PBC $( n = 9 )$ , Grave's disease $f _ { \Pi } = 1 2 ^ { \prime }$ Hashimoto $( \bar { \mathsf { n } } = 1 1 ) ,$ celiac disease $\tan = 1 1 1$ Diabetes Type I $( n = 1 2 )$

Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-Scl-70 antibodies (lgG) were analyzed in a panel of 200 samples from apparently healthy blood donors (120 men and 80 women with an average age of 40 y; age range: 19 - 68 y). The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.01</td></tr></table>

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in his premarket notification s completeand supports a substantial equivalence decision.

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-Centromeres autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay

E. Applicant: EUROIMMUN US INC.

F. Proprietary and Established Names: EUROIMMUN Anti-Centromeres ELISA (IgG)

G. Regulatory Information:

1. Regulation: 21 CFR 866.5110 - Antinuclear antibody immunological test system   
2. Classification: Class II   
3. Product code: LJM   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s): The EUROiMMUN Anti-Centromeres ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against Centromeres in human serum and plasma (EDTA, Li-heparin, Citrate). It isused as an aid in the diagnosis of limited form of progressive systemic sclerosis (CREST syndrome), in conjunction with other laboratory and clinical findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

Device Description: The EUROIMMUN Anti-Centromeres ELISA (IgG) consists of a microwell ELISA plate coated with Cenreres ntiencalibrator positive nd egativcontro, peroxias-labelled antman Igcone sample buffer, wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information:

1. Predicate device name (s): Inova Quanta Lite Centromeres ELISA   
2. Predicate 510(k) number(s): K003959

# 3.Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to Centromeres</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative units</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate.followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>.Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>Recombinant CENP-A and CENP-B</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcalculation of results), 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance orIndustry nd  SRecoendatinsorAntNuclearAntibodyNAes Ssem Premarket $( 5 1 0 ( \mathsf { k } ) )$ Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample buffer, $1 0 0 ~ \mu \vert$ of each diluted patient sample and pre-diluted controls and clibrators aeadded t the antigen coatemicrotier wells anincubatedr30minutes t r temperature. After incubation the microtiter well strips are washed with wash buffer to remove unbound antibodies and $1 0 0 ~ \mu \mu \up$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter well. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with EY $3 0 0 ~ \mu \updownarrow$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 ~ \mu \vert$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu \up$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of 450 nm and a reference wavelength of between 620 nm and 650 nm within 30 minutes.

# Performance Characteristics (where applicable):

# Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day, each run performed according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-Centromeres ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.4 - 4.6</td><td rowspan=1 colspan=1>2.7-2.9</td><td rowspan=1 colspan=1>1.5-1.6</td><td rowspan=1 colspan=1>1.1- 1.2</td><td rowspan=1 colspan=1>0.6-0.6</td><td rowspan=1 colspan=1>0.3-0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 1 0 x 4</td><td rowspan=1 colspan=6>Anti-Centromeres ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.1-5.0</td><td rowspan=1 colspan=1>2.8-3.3</td><td rowspan=1 colspan=1>1.4-1.6</td><td rowspan=1 colspan=1>1.1-1.3</td><td rowspan=1 colspan=1>0.6-0.7</td><td rowspan=1 colspan=1>0.3-0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

The lot o lot eproduciblity was invetigated durig the valaton and qualycontrol  the usin different lots with QC samples distributed over the measurement range. The following results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-Centromeres ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>3.8- 4.5</td><td rowspan=1 colspan=1>4.6-5.3</td><td rowspan=1 colspan=1>3.7-4.2</td><td rowspan=1 colspan=1>0.3-0.3</td><td rowspan=1 colspan=1>0.8-0.9</td><td rowspan=1 colspan=1>1.1- 1.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=4>Anti-Centromeres ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>Sample 10</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>8**</td><td rowspan=1 colspan=1>10**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>10**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>2.2 - 3.3</td><td rowspan=1 colspan=1>5.5-7.0</td><td rowspan=1 colspan=1>4.9- 8.3</td><td rowspan=1 colspan=1>7.8-9.1</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.

C. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design of the Anti-Centromeres ELISA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-Centromeres ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection:

Not applicable.

Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically positive for antibodies against rib.P-P, nRNP/Sm, Sm, SS-A, SS-B, Scl-70, Jo-1, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-Centromeres ELISA (IgG), so no cross reactivity is expected.

Interference: Toinvestigate the inluence from hemoglobn, triglycerides and bilirbn, 5 different s at different anti-Centromeres concentrations (12 - 106 RU/ml) were spiked with potential interfering substances and were incubated with the test system according to the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $9 1 - 1 1 1 \%$ . No significant interference was observed for concentrations of up to $1 0 0 0 \ m g / \mathsf { d } !$ for hemoglobin, $2 0 0 0 \ m g / { \mathsf { d } } |$ for triglyceride, 40 mg/dl for bilirubin and 500 lU/ml for rheumatoid factor.

g. Assay cut-off: Ratio 1.0

2 Comparison studies:

a. Method comparison with predicate device:

A comparison study was performed using 297 clinically characterized samples (144 systemic sclerosis, 2 CREST, 51 Sjögren's syndrome, 15 fibromyalgia, 35 RA, 30 borreliosis and 20 healthy). obtained from different sources from Europe and North America. The panel consisted of $6 1$ men and 230 women. Age ranged from 2 to 87 years with an average age of 50 years. Anti-centromeres antibodies are expected in systemic sclerosis. The other disease groups serve as control cohorts. The samples were tested with the EUROlMMUN Anti-Centromeres ELISA (IgG) and with the Inova Quanta Lite Centromere ELISA as the predicate device. All of the 5 discrepant samples were from control groups.

<table><tr><td colspan="4">All samples</td><td colspan="4">Predicate ELISA</td></tr><tr><td colspan="4">n = 297 EUROIMMUN</td><td colspan="2">positive</td><td colspan="2">negative</td></tr><tr><td>Anti-Centromeres ELISA (IgG)</td><td colspan="4">positive</td><td colspan="2">73</td><td>0</td></tr><tr><td></td><td>negative</td><td></td><td></td><td>5</td><td></td><td></td><td>219</td></tr><tr><td>Negative agreement</td><td>219 {</td><td>219</td><td>=</td><td>100.0%</td><td>95% C.I.:</td><td>98.3%</td><td>100.0%</td></tr><tr><td>Positive agreement</td><td>73 ,</td><td>78</td><td>=</td><td>93.6%</td><td>95% C.I.:</td><td>85.7%</td><td>97.9%</td></tr><tr><td>Overall agreement</td><td>292 1</td><td>297</td><td>=</td><td>98.3%</td><td>95% C.I.:</td><td>96.1%</td><td>99.5%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept O; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.99 and $\%$ recovery compared toserum was in the range of 84 to $108 \%$ $( \mathsf { s e r u m } = 1 0 0 \% )$ .

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>Citrate plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = plasma, x = serum)95% C.I. of intercept95% C.I. of slope</td><td rowspan=1 colspan=1>y = -1.54 + 1.02 x-3.85 - -0.060.98 - 1.08</td><td rowspan=1 colspan=1>y = 0.02 + 0.92 x-2.13 - 0.990.89-0.96</td><td rowspan=1 colspan=1>y = -0.99 + 0.98-2.48 - 0.690.94 - 1.01</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination R²</td><td rowspan=1 colspan=1>0.9958</td><td rowspan=1 colspan=1>0.9973</td><td rowspan=1 colspan=1>0.9978</td></tr><tr><td rowspan=1 colspan=1>Mean %recoveryRange of %recovery</td><td rowspan=1 colspan=1>98 %84 - 108 %</td><td rowspan=1 colspan=1>93 %83 - 101 %</td><td rowspan=1 colspan=1>96 %88 - 107 %</td></tr></table>

3Clinical studies:

Clinical studies were performed in cooperation with different sites. In total 877 clinically characterized samples (280 from systemic sclerosis patients and 597 from control groups) were investigated for anticentromeres antibodies (IgG). With the EUROIMMUN Anti-Centromeres ELISA (IgG) a prevalence of $1 9 . 0 \%$ $9 5 \%$ C.I.: $1 3 . 9 - 2 4 . 9 \% )$ was found in systemic sclerosis, a prevalence of $7 . 3 \%$ $9 5 \%$ C.I.: $3 . 0 \textrm { - }$ $1 4 . 4 \% )$ was found in diffuse systemic sclerosis and a prevalence of $7 4 . 3 \%$ $9 5 \%$ C.I.: $6 5 . 3 - 8 2 . 1 \%$ was found in limited systemic sclerosis with a specificity of $9 9 . 0 \%$ $9 5 \%$ C.I.: $9 7 . 8 - 9 9 . 6 \%$ The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

a.Clinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-Centromeres ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>37.5%</td><td rowspan=1 colspan=1>31.8 - 43.5%</td></tr><tr><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>Diffuse systemic sclerosis (from panel 1)</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>3.0-14.4%</td></tr><tr><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>Limited systemic sclerosis (from panel 1)</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>74.3%</td><td rowspan=1 colspan=1>65.3 - 82.1%</td></tr></table>

Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n.</td><td rowspan=1 colspan=3>Anti-Centromeres ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>181</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>97.0-100.0%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>86.8-100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>96.6- 100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Sjogren&#x27;s syndrome</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>96.6%</td><td rowspan=1 colspan=1>90.4-99.3%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>88.2-99.9%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Borreliosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>597</td><td rowspan=1 colspan=1>591</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>97.8-99.6%</td></tr></table>

\*from the following groups: AlH $( \mathfrak { n } = \mathfrak { 8 } )$ PBC $( n = 9 )$ , Grave's disease $( n = 1 2 )$ , Hashimoto $( n = 1 1 )$ , celiac disease $( n = 1 1 )$ - Diabetes Type $( n = 1 2 )$

C. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-centromeres antibodies (gG) were analyzed in a panel of 200 samples from apparently healthy blood donors (120 men and 80 women with an average age of 40 y; age range: 19 - 68 y). The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>199</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.21</td></tr></table>

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in his premarket notificationis complete and supports a substantial equivalence decision.

Michael Locke

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-Jo-1 autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay   
E. Applicant: EUROIMMUN US INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-Jo-1 ELISA (IgG)

G. Regulatory Information:

1. Regulation: 21 CFR 866.5110 - Antinuclear antibody immunological test system   
2. Classification: Class II   
3. Product code: LLL   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s): The EUROiMMUN Anti-Jo-1 ELISA (IgG) test kit is intended for the qualitative determination of IgG class autntibodies against Jo- in human serum and plasma (EDTA, Li-heparin Citrate) It is usedas an id in the diagnosis of polymyositis and dermatomyositis, in conjunction with other laboratory and clinical findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

I. Device Description:

The EUROIMMUN Anti-Jo-1 ELISA (IgG) consists of a microwell ELISA plate coated with Jo-1 antigen, caliator, positiveand negativecontrol peroxidase-abelled anti-human Gconjugate, ample buff wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information:

1. Predicate device name (s):. Inova Quanta Lite Jo-1 ELISA   
2. Predicate 510(k) number(s): K926562

# 3.Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to Jo-1</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative units</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Purified Jo-1 antigen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controis are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate.followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>1tem</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>&quot;,Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcalculation of results). 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staf: Recommendations for Anti-Nuclear Antibody (ANA) Test System Premarket $( 5 1 0 ( { \sf k } ) )$ Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample buffer, $1 0 0 ~ \mu \mu \up$ of each diluted patient sample and pre-diluted controls and calibrators are added to the antigen coated microtiter well and incubated for 30minutes at rom temperature. After incubation the microtiter wel strips are washed with wash buffer to remove ubound antibodies and $1 0 0 ~ \mu \vert$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter wel. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with EPY $3 0 0 ~ \mu \mu \up$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 ~ \mu \vert$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu \mu \mu$ stop solution is added. The microtiter plates are placed in an ELisA reader and read at a wavelength of $4 5 0 \ \mathsf { n m }$ and a reference wavelength of between $6 2 0 n m$ and 650 nm within 30 minutes.

# M. Performance Characteristics (where applicable):

Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day, each run performed according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-Jo-1 ELISA ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>6.1-6.8</td><td rowspan=1 colspan=1>4.1 - 4.5</td><td rowspan=1 colspan=1>1.6 - 1.9</td><td rowspan=1 colspan=1>1.0 - 1.1</td><td rowspan=1 colspan=1>0.7- 0.8</td><td rowspan=1 colspan=1>0.3 - 0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 10 x 4</td><td rowspan=1 colspan=6>Anti-Jo-1 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample.6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:                .</td><td rowspan=1 colspan=1>5.6-6.6</td><td rowspan=1 colspan=1>3.7- 4.6</td><td rowspan=1 colspan=1>2.0 - 2.3</td><td rowspan=1 colspan=1>1.0-1.2</td><td rowspan=1 colspan=1>0.7-0.8</td><td rowspan=1 colspan=1>0.3-0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

The lot to lot eproduciblity was investigated during the validaton an qualycontrol  the iusi different lots with QC samples distributed over the measurement range. The following results were obtained:   
Lot to lot reproducibility

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-Jo-1 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>4.6-5.4</td><td rowspan=1 colspan=1>3.5-4.4</td><td rowspan=1 colspan=1>1.9-2.2</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1>0.9-0.9</td><td rowspan=1 colspan=1>1.1 - 1.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=4>Anti-Jo-1 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>Sample 10</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>10**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>1.9 - 3.1</td><td rowspan=1 colspan=1>3.2-4.6</td><td rowspan=1 colspan=1>6.4-8.6</td><td rowspan=1 colspan=1>7.7 - 8.9</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.

C. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design of the Anti-Jo-1 ELISA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-Jo-1 ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection:

Not applicable.

f Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically positive for antibodies against rib.P-P, nRNP/Sm, Sm, SS-A, SS-B, Scl-70, centromeres, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-Jo-1 ELISA (IgG), so no cross reactivity is expected.

Interference: Toinvestigate thenfluence from hemoglobn, triglycerides and biliubin, 5different s at different anti-Jo-1 concentrations (15 - 106 RU/ml) were spiked with potential interfering substances and were incubated with the test system according to the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $9 1 - 1 2 2 \%$ . No significant interference was observed for concentrations of up to $1 0 0 0 \ m g / d 1$ for hemoglobin, 2000 mg/dl for triglyceride, 40 mg/dl for bilirubin and 500 lU/ml for rheumatoid factor.

g. Assay cut-off: Ratio 1.0

Comparison studies:

a. Method comparison with predicate device:

A comparison study was performed using 297 clinically characterized samples (143 myositis, 3 PM/SSc, 51 Sjögren's syndrome, 15 fibromyalgia, 35 RA, 30 borreliosis and 20 healthy), obtained from different sources from Europe and North America. The panel consisted of 75 men and 221 women. Age ranged from 14 to 84 years with an average age of 52 years. Anti-Jo-1 antibodies are expected in myositis. The other disease groups serve as control cohorts. The samples were tested with the EUROIMMUN Anti-Jo-1 ELISA (IgG) and with the Inova Quanta Lite Jo-1 ELISA as the predicate device. Both discrepant samples were from myositis patients.

<table><tr><td colspan="4">All samples</td><td colspan="4">Predicate ELISA</td></tr><tr><td colspan="4">n = 297</td><td colspan="2">positive</td><td colspan="2">negative</td></tr><tr><td>EUROIMMUN</td><td colspan="4">positive</td><td>64</td><td colspan="2">1</td></tr><tr><td>Anti-Jo-1 ELISA (IgG)</td><td></td><td>negative</td><td></td><td></td><td>1</td><td></td><td>231</td></tr><tr><td>Negative agreement</td><td>231 1</td><td>232</td><td>=</td><td>99.6%</td><td>95% C.I.:</td><td>97.6%</td><td>100.0%</td></tr><tr><td>Positive agreement</td><td>64 1</td><td>65</td><td>=</td><td>98.5%</td><td>95% C.I.:</td><td>91.7% -</td><td>100.0%</td></tr><tr><td>Overall agreement</td><td>295 ,</td><td>297</td><td>=</td><td>99.3%</td><td>95% C.I.:</td><td>97.6% </td><td>99.9%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept 0; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.98 and $\%$ recovery compared toserum was in the range of 85 to $117 \%$ $( \mathsf { s e r u m } = 1 0 0 \% )$ .

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA plasma</td><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>Citrate plasma</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Concentration range (serum)</td><td rowspan=1 colspan=1>ratio 0.3 - 9.2</td><td rowspan=1 colspan=1>ratio 0.3 - 9.2</td><td rowspan=1 colspan=1>ratio 0.3 - 9.2</td></tr><tr><td rowspan=1 colspan=1>Concentration range (plasma)</td><td rowspan=1 colspan=1>ratio 0.3 - 8.7</td><td rowspan=1 colspan=1>ratio 0.4 - 8.5</td><td rowspan=1 colspan=1>ratio 0.3 - 8.9</td></tr><tr><td rowspan=1 colspan=1>Regression equation(y = plasma, x = serum)</td><td rowspan=1 colspan=1>y = -0.09 + 0.99 x</td><td rowspan=1 colspan=1>y = 0.09 + 0.93 x</td><td rowspan=1 colspan=1>y = 0.73 + 0.99</td></tr><tr><td rowspan=1 colspan=1>95% C.I. of intercept</td><td rowspan=1 colspan=1>-3.77-1.83</td><td rowspan=1 colspan=1>-0.69-1.94</td><td rowspan=1 colspan=1>-0.49-2.66</td></tr><tr><td rowspan=1 colspan=1>95% C.I. of slope</td><td rowspan=1 colspan=1>0.93 - 1.10</td><td rowspan=1 colspan=1>0.89-0.99</td><td rowspan=1 colspan=1>0.96-1.01</td></tr><tr><td rowspan=1 colspan=1>Coefficient of determination R</td><td rowspan=1 colspan=1>0.9856</td><td rowspan=1 colspan=1>0.9956</td><td rowspan=1 colspan=1>0.9982</td></tr><tr><td rowspan=1 colspan=1>Mean %recovery</td><td rowspan=1 colspan=1>101 %</td><td rowspan=1 colspan=1>95 %</td><td rowspan=1 colspan=1>103 %</td></tr><tr><td rowspan=1 colspan=1>Range of %recovery</td><td rowspan=1 colspan=1>85-117 %</td><td rowspan=1 colspan=1>87-113 %</td><td rowspan=1 colspan=1>94- 114 %</td></tr></table>

3Clinical studies:

Clinical studies were performed in cooperation with different sites. In total 876 clinicaly characterized samples (177 from myositis patients and 699 from control groups) were investigated for anti-Jo-1 antibodies (IgG). With the EUROIMMUN Anti-Jo-1 ELISA $( 1 9 G )$ a prevalence of $1 8 . 6 \%$ $9 5 \%$ C.I.: 13.2 - $2 5 . 2 \% )$ was found in myositis with a specificity of $9 9 . 6 \%$ EMPY $( 9 5 \% \mathsf { C l } . : 9 8 . 8 - 9 9 . 9 \% )$ .The results are shown in the table below. $95 \%$ C.I. are calculated by the exact method.

a. Clinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-Jo-1 ELISA (gG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>18.6%</td><td rowspan=1 colspan=1>13.2 - 25.2%</td></tr></table>

Clinical specificity.

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-JO-1 ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>99.1%</td><td rowspan=1 colspan=1>96.6-99.9%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>96.6 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.5-100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Sjogren&#x27;s syndrome</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.9 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>92.1 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Fibromyalgia</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>78.2- 100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Other autoimmune diseases</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Borretiosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>699</td><td rowspan=1 colspan=1>696</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>98.8-99.9%</td></tr></table>

C. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-Jo-1 antibodies (IgG) were analyzed in a panel of 200 samples from apparently healthy blood donors (120 men and 80 women with an average age of $4 0 y ;$ age range: $1 9 - 6 8 y )$ . The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.03</td></tr></table>

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submied information in this premarket notification is complete and supports a substantial equivalen decision.

# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K123261   
B. Purpose for Submission: New device   
C. Measurand: Anti-ribosomal P-proteins autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay

E. Applicant: EUROIMMUN US INC

F. Proprietary and Established Names: EUROIMMUN Anti-ribosomal P-proteins ELISA (IgG)

G. Regulatory Information:

1. Regulation: 21 CFR 866.5110 - Antinuclear antibody immunological test system   
2. Classification: Class II   
3. Product code: MQA   
4. Panel: Immunology

H. Intended Use:

1. Intended use(s):

The EUROlMMUN Anti-ribosomal P-proteins ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against ribosomal $\mathsf { P }$ -proteins in human serum and plasma (ETA, Lihepar, Citate). t is used s n id n thedagnosisof systemic upus eythematos,in conjunction with other laboratory and clinical findings.

2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

I. Device Description: The EUROMMUN Anti-ribosomal P-proteins ELISA (IgG) consists of a microwell ELISA plate coated with roal -protentien clirator, positivn egativcontol peroiase-abelle anti-um IgG conjugate, sample buffer, wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

J. Substantial Equivalence Information:

1. Predicate device name (s): Inova Quanta Lite Ribosomal P ELISA   
2. Predicate 510(k) number(s): K981237

# 3.Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to ribosomal P-proteins</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative units</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>Ali reagents, calibrator and controls are ready to use,except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate,followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>..Semi-quantitative&quot; (using low positive control)</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Purified ribosomal P antigen</td><td rowspan=1 colspan=1>Synthetic ribosomal P antigen</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive. 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 high positive, 1 low positive (used forcalculation of results). 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, Li-heparin, Citrate)</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>20 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staff Recommendations for Anti-Nuclear Antibody (ANA) Test System Premarket $( 5 1 0 ( | \mathsf { K } ) )$ Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201 in sample buffer, $1 0 0 ~ \mu \mu$ of each diluted patient sample and pre-diluted controls an alators de  hentigen coaticotiter wencubatd or utes temperature. After incubation the microtiter well strips are washed with wash buffer to remove unbound antibodies and $1 0 0 \mu$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter well. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with EY $3 0 0 ~ \mu \mu \up$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 ~ \mu \mu \up$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu \up$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of 450 nm and a reference wavelength of between 620 nm and 650 nm within 30 minutes.

# M. Performance Characteristics (where applicable):

Analytical performance:

a. Precision/Reproducibility:

The reproducibility  the test was investigated using sera with different concenrations. Intra-asy reproducibility is based on 20 determinations and inter-assay reproducibility on 40 determinations performed in 10 different runs on 5 days with 2 runs per day, each run performed according to the package insert. The following results were obtained:

Intra-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-ribosomal P-proteins ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.1-6.0</td><td rowspan=1 colspan=1>3.2- 4.1</td><td rowspan=1 colspan=1>1.8-2.1</td><td rowspan=1 colspan=1>1.0 - 1.1</td><td rowspan=1 colspan=1>0.6-0.7</td><td rowspan=1 colspan=1>0.3-0.5</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 1 0 x 4</td><td rowspan=1 colspan=6>Anti-ribosomal P-proteins ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>5.3-6.1</td><td rowspan=1 colspan=1>3.5 - 4.1</td><td rowspan=1 colspan=1>1.7 - 2.2</td><td rowspan=1 colspan=1>1.0-1.3</td><td rowspan=1 colspan=1>0.6-1.0</td><td rowspan=1 colspan=1>0.3 - 0.4</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>100%</td></tr></table>

The lot o lot eproduciblity was investigated durig the valaton and qualy control  the kt sin different lots with QC samples distributed over the measurement range. The following results were obtained:

Lot to lot reproducibility   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=6>Anti-ribosomal P-proteins ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>2.8-3.6</td><td rowspan=1 colspan=1>4.2-4.8</td><td rowspan=1 colspan=1>2.0-2.4</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1>0.8-0.9</td><td rowspan=1 colspan=1>1.0 - 1.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Anti-ribosomal P-proteins ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>Sample 9</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>3.9-5.3</td><td rowspan=1 colspan=1>4.4-6.2</td><td rowspan=1 colspan=1>6.5-8.5</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.

C. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent the "sandwich" formation. Under these conditions, the measured level of analyte may be significantly lower than the actual level present in the sample. The two-step immunoassay design of the Anti-ribosomal P-proteins ELISA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods):

A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-ribosomal P-proteins ELISA was verified using the ANA reference panel of the CDC Centers for Disease Control and Prevention, Atlanta, USA.

e. Limit of detection: Not applicable.

f Analytical specificity:

Cross-reactivity: The quality of the antigen coated on the plates ensures a high specificity of the ELISA. Cross reactivity was investigated using a panel of 30 sera serologically positive for antibodies against nRNP/Sm, Sm, SS-A, SS-B, Scl-70, Jo-1, centromeres, Rubella virus, Measles virus, Herpes simplex virus type 1 and Borrelia burgdorferi. All 30 sera were negative in the Anti-ribosomal Pproteins ELISA (IgG), so no cross reactivity is expected.

Intrerence: Toinvestigate the influence from hemoglobin, trglycerides and bilirubin, 5 different at different anti-ribosomal P-proteins concentrations (13 - 104 RU/ml) were spiked with potential interfering substances and were incubated with the test system according to the package insert. Interferences from rheumatoid factor were investigated similarly by spiking with a RF positive serum. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of $8 4 \mathrm { ~ - ~ } 1 1 5 \mathrm { ~ \% ~ }$ . No significant interference was observed for concentrations of up to 1000 mg/dl for hemoglobin, $2 0 0 0 \ r i 9 / d 1$ for triglyceride, $4 0 m g / d$ for bilirubin and 500 lU/ml for rheumatoid factor.

g. Assay cut-off. Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device.

A comparison study was performed using 243 clinically characterized samples (90 SLE, 1 SLE/SS, 1 CLE, 51 Sjögren's syndrome, 15 fibromyalgia, 35 RA, 30 borreliosis and 20 healthy), obtained from different sources from Europe and North America. The panel consisted of 49 men and 187 women. Age ranged from 14 to 83 years with an average age of 47 years. Anti-ribosomal $\mathsf { P }$ -proteins antibodies are expected in SLE. The other disease groups serve as control cohorts. The samples were tested with the EUROlMMUN Anti-ribosomal P-proteins ELISA (IgG) and with the Inova Quanta Lite Ribosomal P ELISA as the predicate device. All of the 10 discrepant samples were from patients with SLE, SLE/SS, and CLE.

<table><tr><td colspan="4">All samples</td><td colspan="3">Predicate ELISA</td></tr><tr><td colspan="4">n = 243 EUROIMMUN</td><td>positive</td><td colspan="2">negative</td></tr><tr><td rowspan="2">Anti-ribosomal P-proteins ELISA (IgG)</td><td colspan="3">positive</td><td>28</td><td colspan="2">10</td></tr><tr><td>negative</td><td></td><td></td><td>0</td><td></td><td>205</td></tr><tr><td>Negative agreement</td><td>205 1</td><td>215</td><td>=</td><td>95.3% 95% C.I.:</td><td>91.6% -</td><td>97.7%</td></tr><tr><td>Positive agreement</td><td>28 1</td><td>28</td><td>=</td><td>100.0% 95% C.I.:</td><td>87.7%</td><td>100.0%</td></tr><tr><td>Overall agreement</td><td>233 1</td><td>243</td><td>=</td><td>95.9% 95% C.I.:</td><td>92.6%</td><td>98.0%</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using sample pairs each of serum and corresponding plasma (EDTA, Li-heparin, Citrate). Passing-Bablok regression was calculated for the comparison of serum to plasma. The regression equation is near the ideal correlation (intercept 0; slope 1.0) indicating equivalence of concentrations between serum and the corresponding plasma matrices. Coefficients of determination were found to be above 0.99 and $\%$ recovery compared toserum was in the range of 79 to $107 \%$ $\langle \mathsf { s e r u m } = 1 0 0 \% \rangle$ .

<table><tr><td></td><td>EDTA plasma</td><td>Li-heparin plasma</td><td>Citrate plasma</td></tr><tr><td>n Regression equation</td><td>16</td><td>16</td><td>16</td></tr><tr><td>(y = plasma, x = serum) 95% C.I. of intercept</td><td>y = -0.98 + 1.02 x -5.78-0.56</td><td>y = 0.18 +0.98 x -2.42 - 3.26</td><td>y = -1.79 + 0.99 -5.55 - 0.25</td></tr><tr><td>95% C.I. of slope Coefficient of determination R</td><td>0.99 - 1.06 0.9966</td><td>0.92 - 1.03 0.9939</td><td>0.97 - 1.04</td></tr><tr><td>Mean %recovery</td><td></td><td></td><td>0.9959</td></tr><tr><td></td><td>97 %</td><td>98 %</td><td>95 %</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>Range of %recovery</td><td>79 - 107 %</td><td>80- 107 %</td><td>85- 107 %</td></tr></table>

3Clinical studies:

Clinical studies were performed in cooperation with different sites. In total 876 clinically characterized samples (376 from SLE patients and 500 from control groups) were investigated for anti-ribosomal $P$ proteins antibodies (IgG). With the EUROlMMUN Anti-ribosomal P-proteins ELISA $( 1 9 0 )$ a prevalence of $5 . 3 \%$ $9 5 \%$ C.I.: $3 . 3 - 8 . 1 \% )$ was found in SLE with a specificity of $9 9 . 2 \%$ $9 5 \%$ C.I.: $9 8 . 0 - 9 9 . 8 \%$ .The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

a. Clinical sensitivity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-ribosomal P-proteins ELISA (lgG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>376</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>3.3-8.1%</td></tr></table>

Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-ribosomal P-proteins ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>95.3-99.8%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>96.0 -100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.6-100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Sjögren&#x27;s syndrome</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=1>90.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Mixed connective tissue diseases</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>88.2-99.9%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.3-100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Borreliosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>88.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>496</td><td rowspan=1 colspan=1>99.2%</td><td rowspan=1 colspan=1>98.0-99.8%</td></tr></table>

\*from the following groups: AlH ${ \mathfrak { h } } = 8 )$ , PBC $( n = 9 )$ , Grave's disease $( n = 1 2 )$ , Hashimoto $( n = 1 1$ celiac disease $( \mathsf { n } = \mathsf { 1 } \mathsf { 1 } )$ Diabetes Type I $( n = 1 2 )$

Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-ribosomal P-proteins antibodies (IgG) were analyzed in a panel of 150 samples from apparently healthy blood donors (79 men and 71 women with an average age of 38 y; age range: 18 67 ). The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.08</td></tr></table>

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

June 12, 2013

THE BINDING SITE GROUP LTD C/O MS. KATHRYN KOHL MANAGING DIRECTOR 1100 THE AMERICAN ROAD MORRIS PLAINS, NJ 07950

Re: K123261 Trade/Device Name: Euroimmun Anti-nRNP/Sm ELISA (IgG) Euroimmun Anti-Sm ELISA (IgG) Euroimmun Anti-SS-A ELISA $\mathrm { ( l g G ) }$ Euroimmun Anti-SS-B ELISA (IgG) Euroimmun Anti-Scl-70 ELISA (IgG) Euroimmun Anti-Centromeres ELISA (IgG) Euroimmun Anti-Jo-1 ELISA (IgG) Euroimmun Anti-Ribosomal P-Proteins ELISA (IgG) Regulation Number: 21 CFR 866.5110 Regulation Name: Antinuclear Antibody Immunological Test System Regulatory Class: II Product Code: LKO, LKP, LLL, LJM, MQA Dated: May 16, 2013 Received: May 17, 2013

Dear Ms. Kohl:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industrv/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Maria M. Chan -S

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-ribosomal P-proteins ELISA (IgG)

Indications For Use:

The EUROlMMUN Anti-ribosomal P-proteins ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against ribosomal P-proteins in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-nRNP/Sm ELISA (IqG)

Indications For Use:

The EUROIMMUN Anti-nRNP/Sm ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against nRNP/Sm in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of mixed connective tissue diseases and systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.

Concrrence of CDRH; Office of In Viro Diagnostics and Radiological Health OIR)

Division Sign-Off Office of In Vitro Diagnostics and Radiological Health

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-Sm ELISA (IgG)

Indications For Use:

The EUROIMMUN Anti-Sm ELISA (igG) test kit is intended for the qualitative determination of IgG class autoantibodies against Sm in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Maria M. Chan -S

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-SS-A ELISA (IgG)

Indications For Use:

The EUROIMMUN Anti-SS-A ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against SS-A in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of Sjögren's syndrome and systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-SS-B ELISA (IgG)

Indications For Use:

The EUROIMMUN Anti-SS-B ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against SS-B in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of Sjögren's syndrome and systemic lupus erythematosus, in conjunction with other laboratory and clinical findings.

Concurrence of CDRH; Offcef In Viro Diagnostics and Radiological Health OIR)

Maria M. Chan -S

Division Sign-Off Office of In Vitro Diagnostics and Radiological Health

510(k): k123261

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-Scl-70 ELISA (IgG)

Indications For Use:

The EUROIMMUN Anti-Scl-70 ELISA (lgG) test kit is intended for the qualitative determination of IgG class autoantibodies against Scl-70 in human serum and plasma DTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of progressive systemic eos, ncnjuncion wihe boatory an cliial fds.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEDED)

Concurrence f CDRH; Officeof In Vitro Diagnostics and Radiological Health OR)

Maria M. Chan -S

Division Sign-Off Office of In Vitro Diagnostics and Radiological Health

510(k): k123261

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-Centromeres ELISA (IgG)

Indications For Use:

The EUROlMMUN Anti-Centromeres ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against centromeres in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of limited form of progressive systemic sclerosis (CREST syndrome), in conjunction with other laboratory and clinical findings.

# Indications for Use

510(k) Number (if known): k123261

Device Name: Anti-Jo-1 ELISA (IgG)

Indications For Use:

The EUROIMMUN Anti-Jo-1 ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against Jo-1 in human serum and plasma (EDTA, Li-heparin, Citrate). It is used as an aid in the diagnosis of polymyositis and dermatomyositis, in conjunction with other laboratory and clinical findings.

Maria M. Chan -S